Previous Close | 1.5200 |
Open | 1.5400 |
Bid | 1.4100 x 1300 |
Ask | 1.4300 x 800 |
Day's Range | 1.3301 - 1.5400 |
52 Week Range | 1.3300 - 25.5900 |
Volume | |
Avg. Volume | 239,509 |
Market Cap | 37.781M |
Beta (5Y Monthly) | 1.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.0020 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.10 |
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, March 25, 2022 at 10:45 a.m. ET in New York. Webcast information for this event will be accessible on the Events page under the Inv
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.